Ensuring that combination products are effectively managed throughout their development, implementation, launch and post-market surveillance is critical to their long-term success in the market.
However, the interaction between medical device manufacturers and pharma companies arguably still has considerable room for improvement and both face various challenges throughout the product lifecycle. In order to facilitate an efficient development process and launch combination products successfully, the two partners must be fully aligned throughout the product lifecycle.
Ahead of the 2019 Combination Products Forum, Pharma IQ surveyed the industry experts to understand what are the biggest challenges faced by them at each stage of the lifecycle management as well as what’s stopping them from implementing new solutions.
Download this exclusive and new infographic to gain insights on:
- What are the biggest challenges affecting supply chain?
- What are the most difficult challenges in the regulatory landscape?
- What are the challenges with collaboration between medical device and pharmaceutical companies?
- What are the common issues with the usability of combination products?
- What are the problems with post-market surveillance?
- What are the difficulties with implementing new solutions?
Click on 'download' to view the infographic.
Until now, combination products are more often handled inconsistently in different jurisdictions as drugs and/or devices. The determination as to which regulations, submission procedure and pathway to market is followed for the product is largely based on the its Primary Mode of Action, a new concept in itself.
Ahead of the Combination Products Forum 2018, we spoke exclusively to Viky Verna, Co-Founder and Vice President at confinis, in order to discuss the biggest challenges relating to the combination product regulatory landscape, the best compliance management approaches, and the industry’s outlook and direction towards regulation harmonisation.
The global drug device combination product market is expected to reach USD 177.7 billion by 2024. With input from Medical Device Manufacturers, Pharmaceuticals, Consultants and Solution Providers, this report will explore the key drivers and challenges faced in the drug-device combination products market.
Ensuring that combination products are effectively managed throughout their development, implementation, launch and post-launch is critical to long term success in the market. However, there is arguably still considerable room for improvement throughout this process, and in order to facilitate efficiency all parties must be fully aligned throughout the product lifecycle.
In order to explore this topic in more detail, Pharma IQ spoke exclusively to Dr. Tina Rees, Associate Director-Human Factors, Ferring International Pharmascience Center to discuss product lifecycle management and the areas where simple process improvements could make a significant difference to the overall success of a combination product.